Patents by Inventor Vito Palombella

Vito Palombella has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH-INDUCING AGENTS, AND USES THEREOF
    Publication number: 20190062428
    Abstract: The present disclosure relates to combinations of anti-CD47 antibodies and cell death-inducing agents. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the combination.
    Type: Application
    Filed: June 19, 2018
    Publication date: February 28, 2019
    Inventors: Alison PATERSON, Marisa O. PELUSO, Vito PALOMBELLA, Ammar E. ADAM
  • Anti-CD47 antibodies and methods of use
    Patent number: 9650441
    Abstract: Disclosed herein are anti-CD47 antibody molecules, their manufacture and use in treating disorders associated with CD47 expression, for example, certain hematological cancers and solid tumors.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: May 16, 2017
    Assignees: Erasmus University Medical Center, Surface Oncology, Inc.
    Inventors: Frank Grosveld, Vito Palombella, Pamela M. Holland, Alison Paterson, Jonathan Hill
  • ANTI-CD47 ANTIBODIES AND METHODS OF USE
    Publication number: 20170081407
    Abstract: Disclosed herein are anti-CD47 antibody molecules, their manufacture and use in treating disorders associated with CD47 expression, for example, certain hematological cancers and solid tumors.
    Type: Application
    Filed: September 21, 2016
    Publication date: March 23, 2017
    Inventors: Frank Grosveld, Vito Palombella, Pamela M. Holland, Alison Paterson, Jonathan Hill
  • Substituted ?-carbolines
    Patent number: 7348336
    Abstract: The subject matter of the present invention is directed to novel substituted ?-carbolines, and specifically compounds of the formula I, which are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of I?B kinase is involved.
    Type: Grant
    Filed: March 28, 2006
    Date of Patent: March 25, 2008
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Olaf Ritzeler, Alfredo Castro, Louis Grenier, Francois Soucy, Wayne W. Hancock, Hormoz Mazdiyasni, Vito Palombella, Julian Adams
  • Substituted beta carbolines
    Publication number: 20060166978
    Abstract: The subject matter of the present invention is directed to novel substituted beta-carbolines, and specifically compounds of the formula I, which are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of I?B kinase is involved.
    Type: Application
    Filed: March 28, 2006
    Publication date: July 27, 2006
    Inventors: Olaf Ritzeler, Alfredo Castro, Louis Grenier, Francois Soucy, Wayne Hancock, Hormoz Mazdiyasni, Vito Palombella, Julian Adams
  • Substituted beta-carbolines
    Patent number: 7026331
    Abstract: The subject matter of the present invention is directed to novel substituted beta-carbolines, and specifically compounds of the formula I, which are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of I?B kinase is involved.
    Type: Grant
    Filed: July 28, 2003
    Date of Patent: April 11, 2006
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Olaf Ritzeler, Alfredo Castro, Louis Grenier, Francois Soucy, Wayne W. Hancock, Hormoz Mazdiyasni, Vito Palombella, Julian Adams
  • Fc chimeric proteins with anti-HIV drugs
    Publication number: 20050281829
    Abstract: The invention relates to anti viral agents comprised of viral fusion inhibitors and at least a portion of an immunoglobulin constant region. The invention further relates to anti viral agents comprised HIV viral fusion inhibitors and an Fc fragment of an immunoglobulin. The invention also relates to methods of treating a viral infection, including HIV infection.
    Type: Application
    Filed: May 6, 2004
    Publication date: December 22, 2005
    Inventors: Cristina Hehir, Adam Mezo, Robert Peters, James Stattel, Vito Palombella, Alan Bitonti
  • MEKK1 molecules and uses thereof
    Publication number: 20050084884
    Abstract: The invention provides full-length, human isolated nucleic acids molecules, designated MEKK1 nucleic acid molecules, which encode a MEKK family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing MEKK1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a MEKK1 gene has been introduced or disrupted. The invention still further provides isolated MEKK1 proteins, fusion proteins, antigenic peptides and anti-MEKK1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: August 31, 2004
    Publication date: April 21, 2005
    Inventors: Vito Palombella, Sha-Mei Liao
  • INHIBITION OF DRUG BINDING TO SERUM ALBUMIN
    Publication number: 20050037947
    Abstract: The invention relates to improved therapeutics for treating diseases or conditions that provide greater bioavailabilty and more predictable dosing. The invention relates to a chimeric protein comprised of a biologically active molecule linked to an Fc fragment of an immunoglobulin, wherein the chimeric protein binds less serum albumin compared to the same biologically active molecule of the chimeric protein not linked to an Fc fragment of an immunoglobulin.
    Type: Application
    Filed: May 6, 2004
    Publication date: February 17, 2005
    Inventors: Alan Bitonti, Vito Palombella, James Stattel, Robert Peters
  • Substituted beta carbolines
    Publication number: 20040110759
    Abstract: The subject matter of the present invention is directed to novel substituted beta-carbolines, and specifically compounds of the formula I, 1
    Type: Application
    Filed: July 28, 2003
    Publication date: June 10, 2004
    Applicant: AVENTIS PHARMA DEUTSCHLAND GMBH
    Inventors: Olaf Ritzeler, Alfredo Castro, Louis Grenier, Francois Soucy, Wayne W. Hancock, Hormoz Mazdiyasni, Vito Palombella, Julian Adams
  • Substituted beta carbolines
    Patent number: 6627637
    Abstract: The subject matter of the present invention is directed to novel substituted beta-carbolines, and specifically compounds of the formula I, which are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of I&kgr;B kinase is involved.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: September 30, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Olaf Ritzeler, Alfredo Castro, Louis Grenier, Francois Soucy, Wayne W. Hancock, Hormoz Mazdiyashi, Vito Palombella, Julian Adams
  • Substituted beta carbolines
    Publication number: 20020099068
    Abstract: The subject matter of the present invention is directed to novel substituted beta-carbolines, and specifically compounds of the formula I, 1
    Type: Application
    Filed: March 15, 2001
    Publication date: July 25, 2002
    Inventors: Olaf Ritzeler, Alfredo Castro, Louis Grenier, Francois Soucy, Wayne W. Hancock, Hormoz Mazdiyasni, Vito Palombella, Julian Adams